Want to see JP:4575 full AI Analyst Report?

CanBas Co., Ltd. (4575) Price & Analysis

0 Followers

4575 Stock Chart & Stats

¥787.00

-¥23.00(-2.48%)

At close: Jan 08 4:00 PM EST

¥787.00

-¥23.00(-2.48%)

Day’s Range― - ―

52-Week Range¥506.00 - ¥1,558.00

Previous CloseN/A

Volume347.00K

Average Volume (3M)268.48K

Market Cap

¥11.63B

Enterprise Value¥9.66B

Total Cash (Recent Filing)¥2.83B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.97

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-61.17

Shares Outstanding19,713,655

10 Day Avg. Volume208,910

30 Day Avg. Volume268,476

Financial Highlights & Ratios

PEG Ratio1.96

Price to Book (P/B)7.69

Price to Sales (P/S)0.00

P/FCF Ratio-29.34

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt and materially higher equity reduce leverage risk and give the firm structural financial flexibility to fund R&D or absorb setbacks. Over a 2–6 month horizon this supports runway, credit access and partner confidence versus highly leveraged peers.

Licensing / Collaboration ModelA business model focused on licensing, milestones and collaborations creates durable monetization channels without single-product commercialization. Partner-funded development and milestone structures can de-risk cash needs and align incentives for long-term value capture.

Improving Cash Burn TrendThe year-over-year improvement in operating and free cash flow indicates progress reducing burn. If sustained, this trend extends runway, lowers near-term financing frequency and improves the firm's ability to reach value-accretive milestones over the coming months.

Bears Say

Persistent Operating LossesConsistent operating and net losses with negative gross profit show the company is still in a pre-commercial, cash-consuming phase. Over several months this limits internal financing capacity and increases reliance on external capital or partner deals to sustain operations.

Dependence On External FinancingOngoing negative operating and free cash flows create structural dependence on equity or partner funding. That reliance can dilute shareholders, constrain strategic optionality, and expose development timelines to capital market conditions over the medium term.

Minimal Revenue / Commercial TractionRevenue near zero erodes visibility into future royalty or milestone income and means the company lacks demonstrable commercial traction. Structurally, this raises binary development risk and reduces predictable cash inflows over the next several months.

4575 FAQ

What was CanBas Co., Ltd.’s price range in the past 12 months?

CanBas Co., Ltd. lowest stock price was ¥506.00 and its highest was ¥1558.00 in the past 12 months.

What is CanBas Co., Ltd.’s market cap?

CanBas Co., Ltd.’s market cap is ¥11.63B.

When is CanBas Co., Ltd.’s upcoming earnings report date?

CanBas Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 35 days.

How were CanBas Co., Ltd.’s earnings last quarter?

CanBas Co., Ltd. released its earnings results on May 14, 2026. The company reported -¥15.48 earnings per share for the quarter, missing the consensus estimate of N/A by -¥15.48.

Is CanBas Co., Ltd. overvalued?

According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CanBas Co., Ltd. pay dividends?

CanBas Co., Ltd. does not currently pay dividends.

What is CanBas Co., Ltd.’s EPS estimate?

CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CanBas Co., Ltd. have?

CanBas Co., Ltd. has 19,713,655 shares outstanding.

What happened to CanBas Co., Ltd.’s price movement after its last earnings report?

CanBas Co., Ltd. reported an EPS of -¥15.48 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.125%.

Which hedge fund is a major shareholder of CanBas Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4575

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CanBas Co., Ltd.

CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.